☆ 4.2 Article

Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer

Takafumi Shimada et al.

Summary: This study demonstrates the efficacy of combination therapy with Ra-223 and ethinylestradiol (EE) for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC), as evaluated by the decrease in serum prostate specific antigen level.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Treatment Outcomes in Neuroendocrine Prostate Cancer

Hiroaki Iwamoto et al.

Summary: This study investigated the clinical characteristics, clinical course, and treatment outcomes of patients with neuroendocrine prostate cancer (NEPC). Platinum-based chemotherapy is effective to some extent, but the duration of response is not sufficient, indicating the need for new treatment options. SRS findings and the presence of liver metastases might be prognostic predictors of NEPC.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer

Hiroaki Iwamoto et al.

Summary: In castration-resistant prostate cancer patients, the incidence of new visceral metastasis increases significantly with the number of treatments received, resulting in shorter survival time for patients with new metastasis post-treatment. Risk factors for visceral metastasis include T stage, M stage, age, and treatment history.

PROSTATE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Roles of CCL2-CCR2 Axis in the Tumor Microenvironment

Suguru Kadomoto et al.

Summary: Chemokines are a family of cytokines that play important roles in cancer progression. The CCL2-CCR2 axis is a major chemokine signaling pathway that impacts tumor progression significantly.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy

Hiroaki Iwamoto et al.

Summary: Cabazitaxel is recommended as first-line treatment for metastatic castration-resistant prostate cancer, and early introduction of cabazitaxel before sarcopenia and visceral metastasis development may contribute to improved prognosis. Sarcopenia and visceral metastasis are significant factors associated with poor prognosis in patients treated with cabazitaxel.

IN VIVO (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer

Hiroaki Iwamoto et al.

Summary: Vintage hormone therapy as alternative androgen deprivation therapy (AADT) showed effectiveness in certain nmCRPC patients, with over 30% PSA reduction rate, a median response duration of 14.3 months, and potential prolonged overall survival with AADT duration exceeding 18 months. Further studies are needed to identify and differentiate such cases.

IN VIVO (2021)

添加到收藏夹

Article Oncology

Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer

Taito Nakano et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes

Thomas M. Pausch et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Oncology

Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer

Yusuke Shimura et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?

Hiroaki Iwamoto et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Urology & Nephrology

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20-100 ng/mL

Hiroaki Iwamoto et al.

INTERNATIONAL BRAZ J UROL (2019)

添加到收藏夹

Article Oncology

Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital

Kazufumi Nakashima et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Review Medicine, General & Internal

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells

Kouji Izumi et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Immunology

PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling

JunLi Xue et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2019)

添加到收藏夹

Article Oncology

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells

Ariunbold Natsagdorj et al.

CANCER SCIENCE (2019)

添加到收藏夹

Review Urology & Nephrology

Clinical and molecular features of treatment-related neuroendocrine prostate cancer

Shusuke Akamatsu et al.

INTERNATIONAL JOURNAL OF UROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Blockade of CCL2 enhances immunotherapeutic effect of anti-PDl in lung cancer

Yue Wang et al.

JOURNAL OF BONE ONCOLOGY (2018)

添加到收藏夹

Article Urology & Nephrology

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Philip Cornford et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1

Magdalena Czemplik et al.

CURRENT MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Oncology

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer

Kouji Izumi et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma

Zewei Wang et al.

ONCOTARGET (2016)

添加到收藏夹

Article Endocrinology & Metabolism

The Relationship Between Prostate-Specific Antigen and TNM Classification or Gleason Score in Prostate Cancer Patients With Low Prostate-Specific Antigen Levels

Kouji Izumi et al.

PROSTATE (2015)

添加到收藏夹

Article Oncology

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

Igor Tsaur et al.

CANCER RESEARCH AND TREATMENT (2015)

添加到收藏夹

Article Oncology

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

Kouji Izumi et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

Kouji Izumi et al.

EMBO MOLECULAR MEDICINE (2013)

添加到收藏夹

Review Biochemistry & Molecular Biology

Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes

Jun Panee

CYTOKINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Prostate-Cancer Mortality at 11 Years of Follow-up

Fritz H. Schroder et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. De Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann Sebastian de Bono et al.

LANCET (2010)

添加到收藏夹

Article Endocrinology & Metabolism

CCL2 Is Induced by Chemotherapy and Protects Prostate Cancer Cells From Docetaxel-Induced Cytotoxicity

David Z. Qian et al.

PROSTATE (2010)

添加到收藏夹

Review Oncology

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

Matt J. Craig et al.

CANCER AND METASTASIS REVIEWS (2006)

添加到收藏夹

Article Oncology

A midpoint assessment of the American Cancer Society challenge goal to halve the US cancer mortality rates between the years 1990 and 2015

Tim Byers et al.

CANCER (2006)

添加到收藏夹

Article Oncology

CCL2 is a potent regulator of prostate cancer cell migration and proliferation

Robert D. Loberg et al.

NEOPLASIA (2006)

添加到收藏夹

Article Medicine, General & Internal

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

IF Tannock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.